Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Suspended 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 12Gynecologic 3Gastrointestinal 3Breast 3Sarcoma 2NET 2Endocrine 2Thoracic 1Head & Neck 1

Conditions

Neuroendocrine Tumors 3Prostatic Neoplasms 2Carcinoma, Neuroendocrine 2Vulvar Neoplasms 1Thyroid Carcinoma, Anaplastic 1Small Cell Lung Carcinoma 1Sarcoma 1Pheochromocytoma 1Paraganglioma 1Ovarian Neoplasms 1Lung Neoplasms 1Gallbladder Neoplasms 1Breast Neoplasms 1Bile Duct Neoplasms 1Adenocarcinoma 1

Interventions

atezolizumab 2Magnetic Resonance Spectroscopy 2tivozanib 1romidepsin 1pembrolizumab 1pasireotide 1gadoteridol 1gadoterate meglumine 1gadolinium ethoxybenzyl DTPA 1gadodiamide 1gadobutrol 1gadobenic acid 1Specimen Handling 1Respiratory Therapy 1Quality of Life 1Patient Reported Outcome Measures 1PT-100 dipeptide 1Neuropsychological Tests 1Molecular Diagnostic Techniques 1Lactones 1Immunotherapy 1Fluorodeoxyglucose F18 1FAPI-46 1Drug Therapy 1Depsipeptides 1Cabergoline 1Biological Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Prostatic Neoplasms × atezolizumab × NET × Clear all
NCT04471727 2026-02-24

MK-6070-001

Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 1/2 Active not recruiting
232 enrolled
EndocrineGenitourinaryNETThoracic

Lung Neoplasms, Prostatic Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors, Small Cell Lung Carcinoma

NCT05000294 2026-02-18

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

University of Florida

Phase 1/2 Suspended
29 enrolled
BreastEndocrineGastrointestinalGenitourinaryGynecologicNETSarcoma

Bile Duct Neoplasms, Breast Neoplasms, Gallbladder Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Vulvar Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡